Join PCI Biotech for Full-Year 2024 Results Webcast Presentation
PCI Biotech is set to hold an informative webcast presentation to discuss the company's full-year 2024 financial results. This event will take place on Thursday, February 27, 2025, from 08:30 AM to 09:00 AM CET, offering investors and interested parties a chance to engage with the company directly.
How to Access the Webcast
The presentation will be streamed live on the company's official website, inviting participants to join from anywhere. The session will be conducted in Norwegian, highlighting the company's commitment to engaging with its local audience.
Interactive Q&A Session
At the conclusion of the presentation, there will be an interactive Q&A session. Attendees will have the opportunity to submit written questions via the webcast console, allowing for a more personalized experience and direct answers to inquiries regarding the company's performance and future direction.
Where to Find Additional Information
The interim report and accompanying presentation materials will be accessible online from 07:00 AM CET on the same day of the webcast. This gives participants ample time to review the content before delving into discussions during the event.
Contact Information
For further inquiries about the event or other information, please reach out to:
Ronny Skuggedal, CEO / CFO
Contact Email: rs@pcibiotech.no
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech stands at the forefront of biopharmaceutical innovation, concentrating on the development and commercialization of pioneering technologies and treatments through its unique photochemical technology platform. This platform, stemming from elite research at the Oslo University Hospital, showcases the potential for significant advancements in various therapeutic modalities.
Key Technologies in Development
The company is focused on two primary areas of development: Photochemical Lysis (PCL) and Photochemical Internalization (PCI). PCL aims to enhance yield and purity in viral vector manufacturing via selective light-triggered cell lysis. PCI, on the other hand, promotes effective endosomal release stimulated by light, allowing for the exploration of diverse therapeutic modalities.
Strategic Insights and Future Directions
With a robust foundation in research and development, PCI Biotech is committed to exploring new avenues in therapy applications and improving treatment efficacy through its innovative platform. This approach not only highlights its dedication to advancing healthcare solutions but also underscores its position as a pivotal player in the biopharmaceutical arena.
Frequently Asked Questions
What is the date and time of the PCI Biotech webcast?
The webcast is scheduled for February 27, 2025, from 08:30 AM to 09:00 AM CET.
How can I access the presentation?
You can access the presentation live on PCI Biotech's official website.
Will there be a Q&A session?
Yes, there will be an interactive Q&A session at the end of the presentation.
Who can I contact for more information?
You can contact Ronny Skuggedal, CEO / CFO, via email at rs@pcibiotech.no or call +47 9400 5757.
What technologies is PCI Biotech working on?
PCI Biotech is developing Photochemical Lysis (PCL) and Photochemical Internalization (PCI) technologies for innovative therapeutic applications.